^○Arihiro Kiyosue¹, Hiddo Jan L. Heerspink², David C. Wheeler³, Tomoko Ishizu⁴, Min Lin⁵, Emma Wijkmark⁶, Glenn F. Carlson⁵, Anne-Kristina Mercier⁶, Magnus Astrand⁶, Peter J. Greasley⁶, Philip D. Ambery⁶ (1.Tokyo-EKI Center-building Clinic, Tokyo, Japan, 2.Universiteit Groningen, Groningen, Netherlands, 3.University College London, London, United Kingdom, 4.AstraZeneca, Tokyo, Japan, 5.AstraZeneca, Gaithersburg, USA, 6.AstraZeneca, Gothenburg, Sweden)

^○Terumasa Hayashi¹, Silvio E. Inzucchi², Gerasimos Filippatos³, Stefan D. Anker⁴, Christoph Wanner⁵, Tariq Shafi⁶, Navdeep Tangri⁷, Bertram Pitt⁸, Robert Weingold², Meike Brinker⁹, Charlie Scott⁹, Luke Roberts⁹, Peter Rossing¹⁰ (1.Osaka General Medical Center, Japan, 2.Yale School of Medicine, USA, 3.National and Kapodistrian University of Athens, Greece, 4.Charité Universitätsmedizin, Germany, 5.Universitätsklinik Würzburg, Germany, 6.Houston Methodist Academic Institute, USA, 7.Max Rady College of Medicine, Canada, 8.University of Michigan School of Medicine, USA, 9.Bayer, 10.Steno Diabetes Center Copenhagen, Denmark)

^○Hidetoshi Kanai¹, Robert J. Mentz², Stefan D. Anker³, Bertram Pitt⁴, Peter Rossing⁵, Luis M. Ruilope⁶, Martin Gebel⁷, Peter Kolkhof⁷, Robert Lawatscheck⁷, Katja Rohwedder⁷, George L. Bakris⁸ (1.Kokura Memorial Hospital, Japan, 2.Duke University School of Medicine, USA, 3.Charité Universitätsmedizin Berlin, Germany, 4.University of Michigan, USA, 5.Steno Diabetes Center-Copenhagen, Denmark, 6.Institute of Research imas12, Spain, 7.Bayer AG, Germany, 8.University of Chicago Medicine, USA)

^○Yoshitsugu Obi¹, Xiaoqian Zhu¹, Maria Clarissa Tio¹, Timothy, E Yen¹, Michael Hall¹, Neville, R Dossabhoy¹, Tariq Shafi² (1.Department of Medicine, University of Mississippi Medical Center, Jackson, MS, USA, 2.Division of Kidney Diseases, Hypertension, ＆ Transplantation, Houston Methodist Hospital, Huston, TX, USA)

^○Naoki Kashihara¹, Hiroshi Kanegae², Suguru Okami³, Kanae Yoshikawa-Ryan³, Nikolaus G Oberprieler⁴, Manel Pladevall-Vila⁵, J Bradley Layton⁶, Satoshi Yamashita³, Catherine Johannes⁷, Alredo E. Farjat⁸, Csaba P. Kovesdy⁹, David Vizcaya⁴, Yuichiro Yano¹⁰ (1.Department of Nephrology and Hypertension, Kawasaki Medical School, Kurashiki, Japan, 2.Genki Plaza Medical Center for Health Care, Office of Research and Analysis, Tokyo, Japan, 3.Bayer Yakuhin Ltd., Medical Affairs ＆ Pharmacovigilance, Osaka, Japan, 4.Integrated Evidence Generation ＆ Business Innovation, Bayer AG, 13342 Berlin, Germany, 5.RTI Health Solutions, Pharmacoepidemiology and risk management, Barcelona, Spain, 6.RTI Health Solutions, Pharmacoepidemiology and risk management, Research Triangle Park NC, USA, 7.RTI Health Solutions, Pharmacoepidemiology and risk management, Waltham MA, USA, 8.Bayer PLC, Statistics ＆ Data Insights, Reading, United Kingdom, 9.University of Tennessee, Health Science Center, Department of Medicine, Memphis TN, USA, 10.Shiga University of Medical Science, Department of Advanced Epidemiology NCD Epidemiology Research Center, Otsu, Japan)